PE20120315A1 - A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE - Google Patents
A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINEInfo
- Publication number
- PE20120315A1 PE20120315A1 PE2011001882A PE2011001882A PE20120315A1 PE 20120315 A1 PE20120315 A1 PE 20120315A1 PE 2011001882 A PE2011001882 A PE 2011001882A PE 2011001882 A PE2011001882 A PE 2011001882A PE 20120315 A1 PE20120315 A1 PE 20120315A1
- Authority
- PE
- Peru
- Prior art keywords
- esprotonous
- benzimidazole
- biphenyl
- methyl
- candesartan
- Prior art date
Links
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005485 Azilsartan Substances 0.000 title 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 title 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title 1
- 229960002731 azilsartan Drugs 0.000 title 1
- 229960000932 candesartan Drugs 0.000 title 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 title 1
- 229960004349 candesartan cilexetil Drugs 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- -1 BENZIMIDAZOLE COMPOUND Chemical class 0.000 abstract 2
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 abstract 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 abstract 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000004386 Erythritol Substances 0.000 abstract 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229950007556 aranidipine Drugs 0.000 abstract 1
- 229950004646 azelnidipine Drugs 0.000 abstract 1
- 150000001556 benzimidazoles Chemical class 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000019414 erythritol Nutrition 0.000 abstract 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract 1
- 229940009714 erythritol Drugs 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE: A) UN COMPUESTO BENZIMIDAZOL DE FORMULA (I) DONDE R1 ES UN GRUPO HETEROCICLICO QUE CONTIENE NITROGENO MONOCICLICO Y UN ATOMO DE HIDROGENO DESPROTONABLE, R2 ES CARBOXILO OPCIONALMENTE ESTERIFICADO, Y R3 ES ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO; SIENDO COMPUESTOS PREFERIDOS: 1-(CICLOHEXILOXICARBONILOXI)ETIL 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]BENZIMIDAZOL-7-CARBOXILATO, 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO, ACIDO 2-ETOXI-1-[[2'-(4,5-DIHIDRO-5-OXO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO; B) UN ALCOHOL DE AZUCAR TAL COMO MANITOL, SORBITOL O ERITRITOL; C) UN ANTAGONISTA DE CALCIO TAL COMO AMLODIPINA, AZELNIDIPINA, ARANIDIPINA, ENTRE OTROS; Y D) POLIETILENO GLICOL DE PESO MOLECULAR DE 1.000 A 10.000. DICHA COMPOSICION PRESENTA UNA MEJOR ESTABILIDAD DEL DERIVADO BENZIMIDAZOL SIENDO UTIL EN EL TRATAMIENTO DE LA HIPERTENSIONIT REFERS TO A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) A BENZIMIDAZOLE COMPOUND OF FORMULA (I) WHERE R1 IS A HETEROCYCLIC GROUP CONTAINING MONOCYCLIC NITROGEN AND AN ATOMO OF HYDROGEN, AND A SUBSTITUTE INFANT-PROTITLE OPYLUM-OPYLUMOUS RETROGEN, R2 ESPROTONOUS, ESPROTONOUS, SUBSTICIOUS RICHALMENTAL, R2 ESPROTONOUS, ESPROTONOUS, SUBSTICIOUS RICHARDO, R2, ESPROTONOUS, SUBSTITUOUS RICHARDO, R2 ; BEING PREFERRED COMPOUNDS: 1- (CYCLOHEXYLOXYCARBONYLOXY) ETHYL 2-ETOXY-1 - [[2 '- (1H-TETRAZOL-5-IL) BIPHENYL-4-IL] METHYL] BENZIMIDAZOLE-7-CARBOXYLATE, 2-ETOXY-1- [[2 '- (1H-TETRAZOLE-5-IL) BIPHENYL-4-IL] METHYL] -1H-BENZIMIDAZOL-7-CARBOXYL, 2-ETHOXY-1 ACID - [[2' - (4,5-DIHYDRO- 5-OXO-1,2,4-OXADIAZOL-3-IL) BIPHENYL-4-IL] METHYL] -1H-BENZIMIDAZOLE-7-CARBOXYL; B) A SUGAR ALCOHOL SUCH AS MANNITOL, SORBITOL OR ERYTHRITOL; C) A CALCIUM ANTAGONIST SUCH AS AMLODIPINE, AZELNIDIPINE, ARANIDIPINE, AMONG OTHERS; AND D) POLYETHYLENE GLYCOL OF MOLECULAR WEIGHT OF 1,000 TO 10,000. SUCH COMPOSITION PRESENTS A BETTER STABILITY OF THE BENZIMIDAZOLE DERIVATIVE BEING USEFUL IN THE TREATMENT OF HYPERTENSION
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009111381 | 2009-04-30 | ||
| JP2010068625 | 2010-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120315A1 true PE20120315A1 (en) | 2012-04-07 |
Family
ID=43032637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001882A PE20120315A1 (en) | 2009-04-30 | 2010-04-28 | A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP2424501A2 (en) |
| JP (1) | JP5666471B2 (en) |
| KR (1) | KR101797776B1 (en) |
| CN (1) | CN102481248B (en) |
| AU (1) | AU2010242308A1 (en) |
| BR (1) | BRPI1014388A2 (en) |
| CA (1) | CA2760073A1 (en) |
| CL (1) | CL2011002662A1 (en) |
| CO (1) | CO6470841A2 (en) |
| CR (1) | CR20110581A (en) |
| DO (1) | DOP2011000329A (en) |
| EA (1) | EA201171329A1 (en) |
| EC (1) | ECSP11011494A (en) |
| GE (1) | GEP20135940B (en) |
| IL (1) | IL215962A0 (en) |
| MA (1) | MA33280B1 (en) |
| MX (1) | MX2011011011A (en) |
| MY (1) | MY158158A (en) |
| NZ (1) | NZ596395A (en) |
| PE (1) | PE20120315A1 (en) |
| SG (1) | SG175794A1 (en) |
| TW (1) | TWI438201B (en) |
| WO (1) | WO2010126168A2 (en) |
| ZA (1) | ZA201108375B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL236001B1 (en) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, |
| KR101535586B1 (en) * | 2014-08-01 | 2015-07-09 | 에스케이케미칼주식회사 | Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban |
| KR101806004B1 (en) * | 2015-01-30 | 2017-12-08 | 씨제이헬스케어 주식회사 | A pharmaceutical composition comprising candesartan and amlodipine |
| CN106668016B (en) * | 2015-11-11 | 2020-06-23 | 江苏先声药业有限公司 | Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof |
| JP2017210435A (en) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | Method for producing irbesartan and amlodipine besylate-containing tablet |
| JP2019001782A (en) * | 2017-06-14 | 2019-01-10 | 東和薬品株式会社 | Bilayer tablet |
| JP7101464B2 (en) * | 2017-09-28 | 2022-07-15 | エルメッド株式会社 | A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same. |
| CN108210472A (en) * | 2017-12-15 | 2018-06-29 | 蚌埠丰原医药科技发展有限公司 | A kind of Cilnidipine solid dispersions tablet and preparation method thereof |
| CN108685925B (en) * | 2018-05-15 | 2019-12-06 | 徐州医科大学 | Application of a compound AB-38b in the preparation of drugs for treating diabetic nephropathy |
| JP2020075869A (en) * | 2018-11-05 | 2020-05-21 | 日本ケミファ株式会社 | Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients |
| JP7206872B2 (en) * | 2018-12-07 | 2023-01-18 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
| JP2020090471A (en) * | 2018-12-07 | 2020-06-11 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
| JP7441105B2 (en) * | 2020-03-31 | 2024-02-29 | 日本ジェネリック株式会社 | Film-coated tablets containing azilsartan and amlodipine besilate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2814513B2 (en) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | Pharmaceutical composition with improved dissolution |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| JP3057471B2 (en) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | Agent for preventing or treating angiotensin II-mediated diseases |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | Sulphonic derivatives, process for their preparation and their use |
| EP1369130A1 (en) * | 2001-03-16 | 2003-12-10 | Takeda Chemical Industries, Ltd. | Process for producing sustained release preparation |
| EP1452176A4 (en) * | 2001-12-03 | 2009-01-21 | Takeda Pharmaceutical | MEANS FOR IMPROVING INSULIN RESISTANCE |
| TW200306868A (en) * | 2002-05-22 | 2003-12-01 | Shionogi & Co | Composition of hardly soluble medicine with improved solubility |
| EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND USE |
| CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
| TWI396686B (en) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | Cyclic guanamine derivatives, as well as their products and usage |
| JP2006321726A (en) * | 2005-05-17 | 2006-11-30 | Sysmex Corp | Method for controlling elution property of tablet |
| TWI407978B (en) * | 2005-06-27 | 2013-09-11 | Sankyo Co | Method for the preparation of a wet granulated drug product |
| KR101384841B1 (en) * | 2005-06-27 | 2014-04-15 | 다이이찌 산쿄 가부시키가이샤 | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| DE102005031577A1 (en) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist |
| PL2140867T5 (en) * | 2007-03-29 | 2023-10-30 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
| AR073380A1 (en) * | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | SOLID PHARMACEUTICAL COMPOSITION. MULTI-PAD TABLET |
-
2010
- 2010-04-28 MA MA34358A patent/MA33280B1/en unknown
- 2010-04-28 AU AU2010242308A patent/AU2010242308A1/en not_active Abandoned
- 2010-04-28 EA EA201171329A patent/EA201171329A1/en unknown
- 2010-04-28 MY MYPI2011005206A patent/MY158158A/en unknown
- 2010-04-28 GE GEAP201012480A patent/GEP20135940B/en unknown
- 2010-04-28 TW TW099113442A patent/TWI438201B/en active
- 2010-04-28 BR BRPI1014388A patent/BRPI1014388A2/en not_active IP Right Cessation
- 2010-04-28 MX MX2011011011A patent/MX2011011011A/en not_active Application Discontinuation
- 2010-04-28 EP EP10719654A patent/EP2424501A2/en not_active Withdrawn
- 2010-04-28 WO PCT/JP2010/057923 patent/WO2010126168A2/en not_active Ceased
- 2010-04-28 JP JP2011545129A patent/JP5666471B2/en active Active
- 2010-04-28 SG SG2011078391A patent/SG175794A1/en unknown
- 2010-04-28 CN CN2010800289702A patent/CN102481248B/en not_active Expired - Fee Related
- 2010-04-28 NZ NZ596395A patent/NZ596395A/en not_active IP Right Cessation
- 2010-04-28 KR KR1020117027421A patent/KR101797776B1/en active Active
- 2010-04-28 CA CA2760073A patent/CA2760073A1/en not_active Abandoned
- 2010-04-28 PE PE2011001882A patent/PE20120315A1/en not_active Application Discontinuation
-
2011
- 2011-10-26 CL CL2011002662A patent/CL2011002662A1/en unknown
- 2011-10-26 IL IL215962A patent/IL215962A0/en unknown
- 2011-10-26 DO DO2011000329A patent/DOP2011000329A/en unknown
- 2011-11-08 CR CR20110581A patent/CR20110581A/en unknown
- 2011-11-15 ZA ZA2011/08375A patent/ZA201108375B/en unknown
- 2011-11-30 EC EC2011011494A patent/ECSP11011494A/en unknown
- 2011-11-30 CO CO11164599A patent/CO6470841A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102481248B (en) | 2013-12-11 |
| AU2010242308A1 (en) | 2011-12-01 |
| CO6470841A2 (en) | 2012-06-29 |
| CL2011002662A1 (en) | 2012-06-15 |
| EP2424501A2 (en) | 2012-03-07 |
| BRPI1014388A2 (en) | 2016-04-05 |
| ECSP11011494A (en) | 2011-12-30 |
| EA201171329A1 (en) | 2012-05-30 |
| KR20120026060A (en) | 2012-03-16 |
| ZA201108375B (en) | 2013-01-30 |
| DOP2011000329A (en) | 2011-11-15 |
| SG175794A1 (en) | 2011-12-29 |
| MX2011011011A (en) | 2011-11-02 |
| WO2010126168A2 (en) | 2010-11-04 |
| TW201041873A (en) | 2010-12-01 |
| MY158158A (en) | 2016-09-15 |
| CN102481248A (en) | 2012-05-30 |
| JP2012525323A (en) | 2012-10-22 |
| WO2010126168A3 (en) | 2011-03-03 |
| CR20110581A (en) | 2012-01-19 |
| TWI438201B (en) | 2014-05-21 |
| IL215962A0 (en) | 2012-01-31 |
| JP5666471B2 (en) | 2015-02-12 |
| CA2760073A1 (en) | 2010-11-04 |
| GEP20135940B (en) | 2013-10-10 |
| MA33280B1 (en) | 2012-05-02 |
| KR101797776B1 (en) | 2017-11-14 |
| NZ596395A (en) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120315A1 (en) | A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE | |
| PE20120018A1 (en) | PHARMACEUTICAL COMPOSITION OF LINAGLIPTIN AND 1-CHLORINE-4- (B-D-GLUCOPYRANES-1-IL) -2- [4 - ((S) -TETRAHYDROFURAN-3-ILOXI) -BENZYL] -BENZENE, PHARMACEUTICAL FORM AND PROCEDURE FOR ITS PREPARATION | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| PE20120509A1 (en) | DERIVATIVES 9,9 DIFLUORO-9H-FLUORENO HAVING ANTIVIRAL ACTIVITY | |
| CL2011000625A1 (en) | Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation. | |
| AR065850A1 (en) | SOLID PHARMACEUTICAL COMPOSITION INCLUDING A BENZIMIDAZOL-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT | |
| PE20140934A1 (en) | DERIVATIVES OF PIRAZOLE | |
| AR094588A2 (en) | PROCESS FOR OBTAINING A COMPOSITE DERIVED FROM BENZIMIDAZOL AND PHARMACEUTICAL COMPOSITION | |
| PE20080252A1 (en) | USE OF ARYLCARBOXYL ACID BIPHENYLAMIDES FOR THE TREATMENT OF SEEDS | |
| CL2011002697A1 (en) | Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes | |
| PE20081315A1 (en) | BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF VR-1 | |
| PE20120578A1 (en) | S1P5 RECEPTOR AGONISTS AND ANTAGONISTS, AND METHODS OF USE OF THE SAME | |
| PE20080927A1 (en) | BENZOIL-AMINO-HETEROCYCLYL DERIVATIVES AS GLUCOKINASE (GLK) ACTIVATORS | |
| PE20142301A1 (en) | URACILOS BICYCLICALLY REPLACED AND USE OF THE SAME | |
| CO6761298A2 (en) | Combinations comprising atypical antipsychotics and taar1 antagonists | |
| PE20091653A1 (en) | SUBSTITUTE DERIVATIVES OF PIRAZOLE AND THEIR USE | |
| MX2010006565A (en) | Carboxyl- or hydroxyl- substituted benzimidazole derivatives. | |
| CO6400144A2 (en) | AMINOESTER DERIVATIVES OF ALCALOIDS AND MEDICINAL COMPOSITION OF THE SAME | |
| MX2012006106A (en) | Pharmaceutical compositions comprising sigma receptor ligands. | |
| PE20090654A1 (en) | GALENIC FORMULATIONS CONTAINING ALISQUIREN AND VALSARTAN | |
| CR20110093A (en) | [4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy-1h-indole-3-yl] - methanone as a mast cell tryptase inhibitor | |
| AR076300A1 (en) | DERIVATIVES OF PIRIMIDIN REPLACED IMIDAZOLS, INHIBITORS OF GSK3, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME IN THE TREATMENT OF ALZHEIMER, ACUTE NEURODEGENERATIVE DISEASES, DIABETES AND OTHER DISEASES. | |
| AR065714A1 (en) | CHLORHYDRATE SALT OF 5- (3- (3- HYDROXYPHENOXY) AZETIDIN- 1 - IL) - 5 - METHYL - 2, 2 - DIFENYLHEXANAMIDE | |
| PE20121131A1 (en) | SOLID ORAL PHARMACEUTICAL COMPOSITION IN MONOCAPA TABLET INCLUDING IRBESARTAN AND AMLODIPINE BESYLATE | |
| PE20091032A1 (en) | COMPOSITION CONTAINING N- (3-METHOXY-5-METHYLPYRAZIN-2-IL) -2- (4- [1,3,4-OXADIAZOL-2-IL] PHENYL) PYRIDIN-3-SULFONAMIDE (ZIBOTENTAN) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |